Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences
By Colin Kellaher
Regeneron Pharmaceuticals has inked a deal with privately held Mammoth Biosciences to research, develop and commercialize Crispr-based gene-editing therapies targeting multiple diseases.
Regeneron on Thursday said it will make a $100 million up-front payment to Mammoth, including a $95 million equity investment in the biotechnology company.
Tarrytown, N.Y., biotechnology company Regeneron said it will pair its delivery technologies with Mammoth's proprietary Crispr-based gene-editing platform to advance in-vivo programs in multiple tissue and cell types.
Regeneron said Mammoth will be eligible to receive up to $370 million per target in development, regulatory and commercial milestone payments, along with royalties on sales of all collaboration products.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 25, 2024 08:04 ET (12:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?